5.79
0.23 (4.14%)
| Penutupan Terdahulu | 5.56 |
| Buka | 5.64 |
| Jumlah Dagangan | 1,304,624 |
| Purata Dagangan (3B) | 3,504,168 |
| Modal Pasaran | 398,052,224 |
| Harga / Buku (P/B) | 2.29 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Nov 2025 |
| EPS Cair (TTM) | -3.14 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 19.91% |
| Nisbah Semasa (MRQ) | 4.95 |
| Aliran Tunai Operasi (OCF TTM) | -82.77 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -46.26 M |
| Pulangan Atas Aset (ROA TTM) | -40.84% |
| Pulangan Atas Ekuiti (ROE TTM) | -75.45% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | PepGen Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 0.63 |
|
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.27% |
| % Dimiliki oleh Institusi | 95.95% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 20.00 (HC Wainwright & Co., 245.42%) | Beli |
| Median | 10.00 (72.71%) | |
| Rendah | 6.00 (Guggenheim, 3.63%) | Beli |
| Purata | 11.50 (98.62%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 4.51 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 13 Nov 2025 | 20.00 (245.42%) | Beli | 4.89 |
| 27 Oct 2025 | 18.00 (210.88%) | Beli | 5.43 | |
| Wedbush | 30 Sep 2025 | 8.00 (38.17%) | Beli | 4.62 |
| 25 Sep 2025 | 9.00 (55.44%) | Beli | 5.88 | |
| Stifel | 25 Sep 2025 | 12.00 (107.25%) | Beli | 5.88 |
| Guggenheim | 24 Sep 2025 | 6.00 (3.63%) | Beli | 2.66 |
| 09 Sep 2025 | 6.00 (3.63%) | Beli | 1.48 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 12 Nov 2025 | Pengumuman | PepGen Announces Issuance of U.S. Patent for Proprietary PGN-EDODM1 Molecule |
| 12 Nov 2025 | Pengumuman | PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights |
| 03 Nov 2025 | Pengumuman | PepGen to Participate in Upcoming Investor Conferences |
| 02 Oct 2025 | Pengumuman | PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society |
| 26 Sep 2025 | Pengumuman | PepGen Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares |
| 24 Sep 2025 | Pengumuman | PepGen Announces Pricing of $100 Million Public Offering |
| 24 Sep 2025 | Pengumuman | PepGen Announces Proposed Public Offering |
| 24 Sep 2025 | Pengumuman | PepGen Announces Highest Mean Splicing Correction Reported in DM1 Patients |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |